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ABSTRACT
Jurcsisn, Jennifer Grace. M.S., Department of Neuroscience, Cell Biology, and Physiology,
Wright State University, 2014. The CamKKβ inhibitor STO-609 causes artefacts in Ca2+
imaging and selectively inhibits BKCa in mouse carotid body type I cells.
It has previously been reported that AMP-activated protein kinase (AMPK) may be
critical for hypoxic chemotransduction in carotid body type I cells (Wyatt et al, 2007). This
study sought to determine the importance of the regulatory upstream kinase of AMPK,
CamKKβ, in the acute response to hypoxia in isolated mouse type I cells.
Initial studies indicated several previously unreported artefacts associated with using
the CamKKβ inhibitor STO-609 and calcium imaging techniques. Strong STO-609
autofluorescence meant that Fura-2 could not be used and X-Rhod-1 imaging revealed that
STO-609 quenched fluorescence even in the absence of intracellular Ca2+. The whole-cell
configuration of the perforated-patch clamp technique revealed for the first time that STO609 (100µM) rapidly (seconds) inhibited outward macroscopic currents at +10 mV by 38.0%
± 7.4% (n = 5, P<0.03, mean ± SEM) and that this inhibition was abolished in the presence of
the selective BKCa inhibitor paxilline (1 µM).
Taken together these data suggest that STO-609 should be used with caution during
Ca2+ imaging studies as it can directly interact with dyes. The rapid inhibitory effect of STO609 on BKCa was unexpected as the majority of studies using this compound required an
incubation of approximately 10 minutes to inhibit the kinase. Furthermore, as AMPK
activation inhibits BKCa, inhibiting AMPK’s upstream kinases would, if anything, be
predicted to have the opposite effect on BKCa. Future work will determine if the inhibition of
BKCa is via CamKKβ or via an off target action of STO-609 on the channel itself.
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This work has appeared in abstract form at the Ohio Physiological Society meeting 2012,
Experimental Biology 2013 and will be presented in its final form at the 19th meeting of the
International Society for Arterial Chemoreception, Leeds, UK, July 2014.
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I: INTRODUCTION

HISTORY
In the 1600’s, Danish anatomist Jacques-Bénigne Winslow was the first to describe
the Carotid Body (CB) (Kellogg, 1981). After Winslow, Carl Samuel Andersch went on to
explain the CB as a type of “ganglion” in the 1750’s (Kellogg, 1981). Later, Hubert Luschka
improved the anatomical description in 1862, saying the CB was a “gland” due to the
“glandular-looking cells” and the “very fine nerve fibers” associated with them (McDonald,
1981). However, in 1926, some of the most important histological discoveries were made by
Santiago Ramón y Cajal and Fernando de Castro. De Castro stated the CB was able to detect
substances in the blood and had an endocrine-like function; thus, responded by a release of a
secretion (de Castro, 1926). In 1928, he rejected the neurosecretory hypothesis and
embraced a new theory of the CB cells as a sensory mechanism capable of detecting changes
in the blood (de Castro, 1928).
In 1930, Corneille Heymans strove to perfect cross-circulation techniques via
parabiosis. With these experiments, Heymans proved that the chemoreceptors in the CB
elicited a response as a result of the change in the arterial blood composition (Fitzgerald and
Lahiri, 1996). The parabiosis was demonstrated by connecting the arteries of canine A, to
the head of canine B (see figure 1). Upon exposing canine A to hypoxia, it was canine B that
responded by hyperventilating (Heymans et al, 1930). Heymans determined that it was the
carotid bodies that were mediating the hyperventilatory response. For this pioneering work,
Heymans won the Nobel Prize in 1938 (Fitzgerald and Lahiri, 1996).

1

Figure 1
Heymans’ experiment in which two living canines were attached via parabiosis. The thoracic
vessels of Canine A were connected to the cervical vessels of Canine B. Canine A was
subjected to hypoxic conditions resulting in a hyperventilatory response by Canine B.
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ANATOMY
The Carotid Bodies (CB) are small oxygen sensing organs that can be found at the
bifurcation of the common carotid arteries. These organs function as chemoreceptors by
detecting arterial partial pressure of oxygen (PO2), partial pressure of carbon dioxide (PCO2)
and pH levels. They largely contribute to the hyperventilatory response seen during hypoxia,
hypercapnia and metabolic acidosis (Gonzalez et al, 1994).
Ganglioglomerular nerves, branches of the superior cervical ganglion (SCG), provide
sympathetic innervation to the CB, and are also the main efferent component in regulating
blood flow to the bifurcation (Gonzalez et al, 1994). The carotid sinus nerve (CSN), a branch
of the glossopharyngeal nerve, joins with filaments of the vagus nerve to provide both
sympathetic and parasympathetic influence over the CB (Gonzalez et al, 1994). The CSN
exits the CB and its cell bodies lie in the Petrosal ganglion. Projections of the CSN terminate
ipsilaterally and bilaterally in the nucleus of the solitary tract via the Glossopharyngeal nerve,
acting as the main source of afferent input (Finley and Katz, 1992). The action potential is
then propagated to communicate with the central pattern generator to supply motor neurons
innervating the diaphragm via the phrenic nerve. The frequency of generated action
potentials is regulated by the release of neurotransmitters from the CB, which ultimately
controls the hyperventilatory response to hypoxia.
The ultrastructure of the parenchyma in the CB is composed of two types of cells:
Type I cells (glomus) and Type II cells (sustentacular) (Lahiri et al, 2006) (see figure 2). The
Type I cells populate a majority of the CB, as they are the primary source of sensory
receptors accountable for the detection of inappropriate arterial PO2, PCO2 and pH levels
(Stea and Nurse, 1991, Heymans et al, 1930). The Type I cells are responsible for the release
4

of the neurotransmitters mentioned previously. Upon the falling of PO2 and pH levels, or the
rising of PCO2 levels, Type I cells respond to this detection by discharging neurotransmitters
and initiating an action potential down the CSN. There is also some evidence that cellular
communication occurs between Type I cells and nerve endings via gap junctions (McDonald,
1981). The function of Type II cells, on the other hand, is thought to be comparable to that
of a glial cell in the nervous system.

TYPE I CELL SIGNAL TRANSDUCTION
Carotid Body Type I cells’ hypoxic-excitation reaction is correlated with O2 sensitive
ion channels, specifically K+ channels (Shimoda and Polak, 2010). Similar to the rat, two
types of chemosensitive K+ channels exist in the mouse: the high-conductance Ca2+dependent K+ channels (BKCa) and the TASK-like background K+ channels (Ortega-Sáenz,
2010, Yamaguchi, 2004). Inhibition of these K+ channels, as a result of exposure to hypoxic
conditions, leads to a membrane depolarization. When the outward-moving potassium
currents decrease, the cell membrane depolarizes and voltage-gated Ca2+ channels open as a
result, causing an influx of Ca2+ (Buckler and Vaughan-Jones, 1994). The rise in intracellular
[Ca2+] subsequently induces exocytosis and the release of neurotransmitters from the Type I
Cells (Gonzalez et al, 1994). This stimulates excitatory post-synaptic potentials (EPSPs) in
the carotid sinus nerve (CNS), which communicates with the respiratory centers in the brain
to adjust breathing patterns and ultimately return blood oxygen levels to homeostasis,
completing the negative feedback loop. (See Figures 2 and 3). Currently, there are two
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existing hypotheses that attempt to explain the underlying cause of the K+ channels’
inhibition: the membrane hypothesis and the mitochondrial hypothesis.

6

Figure 2
A schematic demonstrating the anatomical location of the carotid body (CB). A. The CB
shown at the bifurcation of the common carotid artery (CCA), lying on the internal carotid
artery (ICA) across from the external carotid artery (ECA). B. Type I cells enveloped by
type II cells in the CB. Type I cells are innervated by the carotid sinus nerve (CSN).
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MEMBRANE HYPOTHESIS
During hypoxia, plasma membrane K+ channels are inhibited (Lopez-Barneo et al,
1988). This inhibition leads to Type I cell depolarization and an increase in intracellular Ca2+
via the opening of voltage-gated Ca2+ channels. There are many classes of K+ channels that
exist; however, the specific K+ channels that contribute to the depolarization of the Type I
cells vary from species to species (Prabhakar, 2000). For the sake of brevity only the two
types of K+ channels, which are chemosensitive in the rat, will be discussed. While it is
known that the mouse shares these two chemosensitive K+ channels (Ortega-Sáenz, 2010,
Yamaguchi, 2004), they vary from strain to strain and have not been fully characterized. As
such, the following research focuses on the rat.
It has been suggested that the first type of channel, high-conductance Ca2+ dependent K+ (BKCa) channels, plays an important role in regulating the hypoxic response of
Type I cells (Peers, 1990). Some BKCa channels can be found in the open state at resting
membrane potential, thus implying a possible function in propagation of action potentials
(Lahiri et al, 2006, Wyatt & Peers, 1995). Williams et al (2004) describe an enzyme that is
responsible for oxygen sensing known as hemeoxgenase-2 (HO-2), which has a primary
purpose of creating carbon monoxide (CO). BKCa channels are activated by this CO
resulting from the work of the HO-2 (Williams et al, 2004, Kemp, 2005). In a hypoxic
situation, however, CO levels become so low it is impossible to sustain activation of BKCa
channels in Type I cells (Kemp 2005). Interestingly enough, Ortega-Saenz et al (2006) used
HO-2 null mice to show unchanged CB output in response to hypoxia, thus proposing that
HO-2 may not be the sole O2 sensor, or involved at all.
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A second type of O2-sensing K+ channel was discovered to be open at resting
membrane potential in Type I cells known as Twik-related acid sensing K+ (TASK-like)
channels (Lahiri et al, 2006). Although these channels were first thought to be voltageinsensitive background K+ channels (Buckler, 1997), it was later discovered these channels
bared a similar resemblance to TASK channels, hence the name “TASK-like” (Buckler et al,
2000). There are a variety of TASK-like channels expressed in Type I cells including
TASK-1, TASK-3 and a TASK-1/TASK-3 heteromer (Kim et al, 2009). The heteromer is
accountable for a majority of the oxygen-sensing background K+ current according to Kim et
al (2009). Hypoxia leads to an inhibition of TASK channels resulting in depolarization of
Type I cells and ultimately causing an influx of [Ca2+]i (Buckler et al, 2000, Buckler, 1997).
In addition to hypoxic conditions, mitochondrial uncouplers and inhibitors are also known to
inhibit TASK channel activity. Moreover, these channels are sensitive to mitochondrial
metabolism, providing the implication that they are capable of detecting O2 levels in blood
by way of a mitochondrial mechanism rather than a membrane-delimited one. This
demonstrates the potential necessity of mitochondria for hypoxic inhibition of the
chemosensitive TASK-like channels in Type I cells of the CB (Buckler, 2006).
There are some pharmacological and patch-clamp studies that indicate the membrane
alone is not solely responsible for Type I cell depolarization. Using various patch-clamp
techniques, it has been demonstrated that hypoxia affects BKCa channels differently. RiescoFagundo et al (2001) demonstrated that BKCa channels of Type I cells are sensitive to
hypoxia with the whole-cell and inside-out configuration. However, Wyatt and Peers (1995)
showed when using the outside-out patch-clamp configuration, the same channels were no
longer sensitive to hypoxia. These different results illustrate that an important factor is lost
10

from the contents of the cytoplasm and suggests another component is necessary for
depolarization.

MITOCHONDRIAL HYPOTHESIS
Mitochondria are able to produce ATP via the process of oxidative phosphorylation.
This is possible given that oxygen serves as the final electron acceptor in cellular respiration.
When oxygen levels are low, cells cannot rely solely on oxidative phosphorylation and must
fall back on other mechanisms for energy production. Demonstrating the vital role oxygen
plays in this process led to the development of the mitochondrial hypothesis of Type I cell
chemotransduction, (Lahiri et al, 2006). Mills and Jobsis (1972) showed further support for
this hypothesis by suggesting that specific complexes of mitochondria in Type I cells must
have a low affinity for oxygen in order for oxygen sensing to occur. Depolarization of the
mitochondrial membrane in Type I cells occurs during hypoxia at 60 mm Hg O2; however, in
non-oxygen-sensing chromaffin cells of the adrenal gland and sensory neurons of the dorsal
root ganglion, depolarization of the mitochondrial membrane does not occur until an almost
anoxic state is reached at 5 mm Hg O2 (Duchen and Biscoe, 1992a, Duchen and Biscoe,
1992b). These studies demonstrate that the response to hypoxia of mitochondria in Type I
cells is specialized.
The effects of hypoxia cause an increase in [Ca2+]i in Type I cells which ultimately
leads to a release in neurotransmitters acting post-synaptically on the CSN. Some compounds
have been used to pharmacologically mimic these effects of hypoxia, such as mitochondrial
electron transport chain inhibitors and uncouplers, as well as ATP synthase inhibitors. This
11

was first demonstrated in 1931 when Heymans et al used cyanide, a recognized
mitochondrial IV complex inhibitor in order to increase CB activity. An ATP synthase
inhibitor, Oligomycin, was used to inhibit ATP mitochondrial production, ultimately
uncovering a connection between the function of mitochondria and increased activity of the
CSN due to hypoxia (Wyatt and Buckler, 2004). Specific mitochondrial inhibitors also cause
an increase in [Ca2+]i in addition to inhibition of background K+ channels (Wyatt and
Buckler, 2004). These mitochondrial inhibitors also prevent Type I cells from responding to
hypoxia suggesting a similar mechanism mediating both of these processes (Mulligan et al,
1981).
It is not well understood how the mitochondria of Type I cells couple to the K+
channels of the plasma membrane, however, one theory suggests ATP regulates TASK-like
K+ channels such that when there is a decrease in ATP levels, K+ channels become inhibited
(Varas, Wyatt and Buckler, 2007). As a result of decreased ATP levels caused by hypoxia,
there is an increase in cellular AMP/ATP ratio, ultimately leading to the activation of
adenosine monophosphate-activated protein kinase (AMPK). This activation of AMPK
causes inhibition of K+ channels which then depolarizes the cell and opens voltage-gated
calcium channels. The resulting calcium influx induces exocytosis, releasing
neurotransmitters from the CB Type I cells (Evans, 2006, Wyatt et al, 2007). (See Figure 3.)
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Figure 3
A schematic illustrating hypoxic chemotransduction within a CB Type I cell. Low blood
oxygen levels caused by hypoxia results in reduced mitochondrial ATP production and
subsequent activation of AMPK. AMPK inhibits K+ channels, depolarizing the cell and
opening voltage-gated Ca2+ channels. The influx of Ca2+ induces exocytosis and
neurosecretion which allows the CB to communicate with the respiratory centers in the brain
via the CSN, mediating breathing and returning blood oxygen to homeostasis.
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AMPK
Adenosine monophosphate-activated protein kinase (AMPK) has been identified as a
master regulator of energy balance throughout the body (Hardie, 2008). Recent evidence
suggests that AMPK can also influence neuronal excitability (Ross, 2011) by regulating a
multitude of ion channels, including TASK3 and BKCa (Dallas, 2009; Ross, 2011).
Moreover, there is increasing evidence that AMPK is critical in the transduction cascade
whereby hypoxic inhibition of K+ channels causes depolarization and subsequent
neurotransmitter release from CB Type I cells (Evans, 2006, Wyatt et al, 2007). Activation of
AMPK is dependent on one of its three known upstream kinases: LKB1 (Hawley, 2003,
Woods, 2003), CamKKβ (Hawley, 2005, Woods, 2005), and TAK1 (Momcilovic, 2006) (See
Fig 4). These upstream kinases phosphorylate AMPK at the threonine-172 (Thr-172) location
on the catalytic alpha subunit (Carling, 2008, Fogarty, 2010). Once activated, AMPK is then
free to phosphorylate different targets, including the aforementioned background, TASK-like
K+ channels and BKCa channels. This suggests that inhibition of the upstream kinases of
AMPK may attenuate the hypoxic response in CB Type I cells.
The compound STO-609 has been widely used as a selective pharmacological
inhibitor of CamKKβ in a variety of preparations (Hawley, 2005, Tamas, 2005, Tokumitsu,
2002). The crystallized structure of the STO-609-CamKKβ complex shows that STO-609
binds near the ATP-binding site of the kinase, inducing structural changes that result in a
closed conformation state (Kukimoto-Niino et al, 2011). This specific inhibitor has been used
in in conjunction with calcium imaging experiments (Monteiro, 2008, Wayman, 2004) as
well as electrophysiological recordings (Tamas, 2006, Schmitt, 2005). Therefore, STO-609
seemed suitable for examining the potential role of CamKKβ as a regulator in the hypoxic
15

chemotransduction of Type I cells. If CamKKβ is inhibited by STO-609, the AMPK
activation cascade will be disrupted, allowing the chemosensitive K+ channels that would
normally close under hypoxic circumstances to stay open, inhibiting depolarization of the
cell membrane and subsequent influx of Ca2+. The hypoxic response would then ultimately
be attenuated.

16

Figure 4
A schematic showing the activation of AMPK by upstream kinases via phosphorylation of
the Thr-172 on the alpha-subunit. AMPK is then able to phosphorylate K+ channels,
inhibiting them and causing membrane depolarization and Ca2+ influx through voltage-gated
Ca2+ channels.
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HYPOTHESIS
It has been shown that AMPK may play a role in the chemotransduction of hypoxia in
the carotid bodies. AMPK is activated by upstream kinases such as LKB1 and TAK1. It can
also be activated by a Ca2+ mediated pathway involving CamKKβ through phosphorylation
of Thr-172 in an AMP-dependent manner. It is anticipated that if CamKKβ is required for a
full response to hypoxia, then its inhibition via the selective CamKKβ inhibitor STO-609 will
attenuate this response.

SUMMARY
The Type I cells of the carotid body, located at the bifurcation of the common carotid
artery, are chemosensors, possessing the ability to detect changes in the levels of pH, CO2
and O2 in arterial blood composition. Upon hypoxic exposure, the Type I cells depolarize
potentially through an AMPK-regulated mechanism, resulting in the release of
neurotransmitters which communicate with the brain to correct breathing patterns and restore
homeostasis. This cellular cascade involving AMPK may also be governed by the upstream
kinases of AMPK, including CamKKβ. Inhibiting this AMPKK with the compound STO-609
may cause an attenuation of the hypoxic response.
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II: MATERIALS AND METHODS
All studies described in this paper were performed in accordance with protocols
approved by the Wright State University Institutional Laboratory Animal Care and Use
Committee (IACUC). These protocols are in accordance with the National Institute of
Health guide for the care and use of laboratory animals (NIH publications No. 80-23) revised
1996.

DISSECTION AND DISSOCIATION OF MOUSE CAROTID BODY TYPE I CELLS
On days of experimentation, two to five adult mice (25 – 35 g) were individually
placed into a chamber and quickly euthanized with a rising concentration of CO2. Using a
dissection microscope (Omâna, Japan) under low magnification, the legs of the mouse were
taped down and secured. Two incisions were made between the shoulders and along the
sternum to expose the subcutaneous fascia. After removal of the local skin, the salivary
glands and lateral tracheal muscles were cut and removed using fine forceps and scissors
(Moria, Fine Science Tools, USA) to reveal the common carotid arterial bifurcation. The
overlying vagus nerve was snapped. The entire carotid bifurcation containing the carotid
body tissue was then carefully removed and placed directly into ice-cold, Dulbecco’s
phosphate buffered saline (DPBS) without Ca2+ or Mg2+ (Sigma). The carotid bifurcations
were then dissected further, separating the arterial and connective tissues from the carotid
body tissue using fine forceps underneath the Omâna dissecting microscope. After taking tail
snips of each mouse for PCR, the carcasses were disposed of according to the Lab Animal
Research specifications.
20

The cleaned carotid bodies were placed in a digestive enzyme solution (0.4mg ml-1
collagenase type I, 220u mg-1 (Worthington Biochemical Corporation), 0.2mg ml-1 trypsin
type I, 8550 BAEE u mg-1 (Sigma)) in DPBS with low CaCl2 (86 μM) and MgCl2 (350 μM)
for 20 minutes at 37°C to digest the connective tissue holding the carotid body together. The
carotid bodies were teased apart and incubated again at 37°C for 7 minutes. After this final
digestion, the carotid body tissue was removed from the Petri dish using a fire-polished,
silanized (Sigmacote, Sigma) Pasteur pipette and placed into a test tube. The tissue was
triturated and centrifuged at 770 rpm (200 x g) for 5 minutes. The cells were then resuspended in tissue culture medium (Ham’s F12 (Sigma) supplemented with 10% heat
inactivated fetal bovine serum (Biowest)), centrifuged again for 5 minutes at 770 rpm (200 x
g), re-suspended in tissue culture medium, and plated onto 12 mm diameter, matrigel (BD
Biosciences) coated glass coverslips. The growth factor reduced, phenol-red free matrigel
prep was used. 57 µL matrigel aliquots were thawed and diluted with 220 µL ice cold F-12
Ham’s nutrient medium (Sigma) before plating 30-50 µL onto the center of the coverslips.
Slips were maintained at 37°C in a humidified, 5% CO2/air incubator. Cells were allowed to
adhere for two hours, and all cells were used for experimentation within eight hours.

CULTURE METHOD OF N2A CELLS
Mouse neuroblastoma cells (N2A) lines were maintained, split (1:20 ratio), and
grown the week prior to usage. On the day of experimentation, the 75 mm2 Tissue Culture
flask (Corning) containing the cells was removed from the 37°C, humidified, 5% CO2/air
incubator. The remaining growth media in the flask taken from a stock comprised of 250 ml
DMEM with high glucose (Gibco Life Technologies), 250 ml Opti-MEM + GlutaMAX
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(Gibco Life Technologies), 25 ml 5% Fetal Bovine Serum (BioWest) and 5 ml
penicillin/streptomycin solution (10,000 units/ml penicillin 10,000 μg/ml streptomycin)
(Gibco Life Technologies) was removed and the cells were rinsed with 5 ml Phosphate
Buffered Saline (Gibco Life Technologies). 2 ml of 0.25% Trypsin-EDTA (Gibco Life
Technologies) was added and allowed to incubate at 37°C for 2 minutes to loosen the cells
from the flask. 5 ml of the growth media was added to stop digestion and the cells were
drawn up and placed in a 50 ml tube. The cells were centrifuged at 750 rpm for 5 minutes.
After removing the supernatant, the pellet was resuspended in 10 ml of the growth media and
plated in 50 μl increments onto 35 mm diameter Fluoro dishes with 10 mm diameter cover
glass bottoms (World Precision Instruments) coated with poly-d-lysine (0.01% w/v). All
procedures were performed within a fume hood under sterile conditions.

CALCIUM IMAGING EXPERIMENTS – FURA-2
Isolated Type I cells were loaded with the Ca2+-sensitive fluorescent dye FURA-2AM (5 μM, Invitrogen) in an extracellular solution of composition (in mM): NaCl, 140; KCl,
4.5; CaCl2, 2.5; MgCl2, 1; glucose, 11; HEPES, 11; pH 7.4 with NaOH. After removing the
remaining media from the cells, the coverslips were added to the dishes containing the
prepared dye solution. The cells were left for 30 minutes to allow the dye to permeate the
cells. The slips were then rinsed in another dish containing 3 ml HEPES solution and
transferred to a third dish of 3 ml HEPES solution in which they rested for another 10-15
minutes to allow the cells time to cleave the –AM groups from the dye. For each rest period,
the cells were kept in a drawer to minimize light exposure.
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Coverslips were mounted in a chamber (0.4 ml, RC-25F, Warner Instruments) and
perfused at 8 ml/minute with extracellular solution of composition (in mM): NaCl, 140; KCl,
4.5; CaCl2, 2.5; MgCl2, 1; glucose, 11; HEPES, 11; pH 7.57 with NaOH. Cells were
visualized with a Nikon TE 2000U inverted microscope with a CFI super fluor x40 oil
immersion objective. The Fura-2 loaded cells were excited with 50 msec exposures to 340
nm and 380 nm light at 0.2 – 0.5 Hz using a Lambda 10-3 filter wheel (Sutter). The filtered
light was reflected up to the cells by way of a 400 DCLP dichroic mirror (Chroma). The
emitted fluorescence measured at 510 nm was then allowed to pass through the Fura-2 Set
filter (Chroma) and be captured using a CoolSNAP HQ2 CCD camera (see Figure 6). Neutral
density filters of 0.7 optical density (Chroma) were placed in the excitatory light path to
prevent any photodamage to cells. Data acquisition and analysis was controlled using
Metafluor 7.1.2 imaging software (Molecular Devices) (see Figure 5). Fluorescence levels
were measured before, during, and after perfusing STO-609 (100 μM, Tocris) over the cells
for approximately ten minutes.
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Figure 5
Schematic illustrating the lab setup for the calcium imaging experiments.
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Figure 6
Figure illustrating the Fura-2 dichroic filter transmission. Fura-2 emission is high when
excited with 340 light when Ca2+ is bound, conversely, its emission is high when excited
with 380 light when Ca2+ is unbound. It emits fluorescence in the range of 510 nm. The grey
line represents the dichroic mirror, reflecting the 340 and 380 nm light, and letting pass the
510 nm light.
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CALCIUM IMAGING EXPERIMENTS – X-RHOD-1
Isolated Type I cells were loaded with the Ca2+-sensitive fluorescent dye X-Rhod-1AM (5 μM, Invitrogen) using the same procedure as Fura-2.
The X-Rhod-1 loaded cells were excited with 50 msec exposures to 580 nm light at
0.2 Hz reflected up to the cells by way of a Texas Red dichroic mirror (Chroma). The emitted
fluorescence measured at 602 nm was then allowed to pass through the dichroic mirror and
be captured using a CoolSNAP HQ2 CCD camera (see Figure 7). Neutral density filters were
reduced to 0.2 optical density (Chroma) to improve the signal. Fluorescence levels were
measured before, during, and after perfusing STO-609 (100 μM, Tocris) over the cells for
approximately ten minutes. For these experiments, a Type I cell excited by a high K+
extracellular solution of composition (in mM): NaCl, 64; KCl, 80; CaCl2, 2.5; MgCl2, 1;
glucose, 11; HEPES, 11; pH 7.57 at 24º C with KOH were used, as well as unexcited N2A
cells. All other imaging and recording parameters were identical to those used for the Fura-2
experiments.
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Figure 7
Figure illustrating the X-Rhod-1 dichroic filter transmission. X-Rhod-1 emission is high
when excited with 580 light when Ca2+ is bound. It emits fluorescence in the range of 602
nm. The grey line represents the dichroic mirror, reflecting the 580 nm light, and allowing to
pass the 602 nm light.
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CALCIUM IMAGING EXPERIMENTS – IONOMYCIN
Experiments were also conducted both in cells loaded with Fura-2 and X-Rhod-1 at
zero [Ca2+]i by perfusing cells with the extracellular solution described previously, but with
Ca2+ removed and 10 mM EGTA and 2 μM of the calcium ionophore ionomycin added.
After applying the solution containing ionomycin, Ca2+ levels were allowed to reach a zero
baseline before applying STO-609 (100 μM, Tocris) in conjunction with the modified
extracellular solution. Fluorescence emission levels were measured throughout this process,
as well as upon removal of the drug.

IMAGING DATA ANALYSIS
The dissociation procedure utilized here predominantly yields individual Type I cells.
Occasionally clusters of cells were observed, but these were not recorded from as locally
released neurotransmitters could affect the nearby cells and this could confuse any results
obtained. Regions of interest (ROI) were drawn over the isolated cells using Metafluor
software and the fluorescence signal was taken as the average within the ROI. Data were
background subtracted. Application of STO-609 was only performed once per coverslip to
avoid any possible sensitization or desensitization effects.
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ELECTROPHYSIOLOGY EXPERIMENTS
Isolated Type I cells were mounted in a chamber (0.4 ml, RC-25F, Warner
Instruments) and perfused at 8 ml/minute with extracellular solution of composition (in mM):
NaCl, 117; KCl, 4.6; CaCl2, 2.5; MgCl2, 1; glucose, 11; NaHCO3, 23; pH 7.57 via bubbling
with CO2. Cells were visualized with a Nikon TE 2000U inverted microscope. The
traditional whole-cell configuration of the patch clamp technique was used (see Figure 8).
Data were acquired using an Axopatch 200B amplifier (Molecular Devices). Currents were
digitized at 5 kHz and filtered at 1 kHz. Experiments were performed at 35-37°C. Results
were not leak subtracted, seal resistance was typically >5 GΩ, access resistance was typically
20-30 MΩ and was not compensated, and holding currents were typically less than 20 pA
throughout the recordings. All data were recorded using Clampex v10.0 software and
analyzed using Clampfit v10.0 software (Molecular Devices). All experiments were carried
out on an anti-vibration microscopy table (TMC).
Micropipettes were made from 1.5 mm O.D. x 0.86 mm I.D. borosilicate glass
capillaries (Harvard Apparatus) inserted into a Narishige PC-10 Puller. The tips were
polished using a Narishige MF-900 Microforge and the ends were fire-polished using a
methanol lamp. Only micropipettes with tip resistances between 5 and 12 MΩ were used.
After carefully dipping the tips in an intracellular solution of composition (in MM): NaCl,
10; KCl, 130; CaCl2, 1; MgSO4, 2; EGTA, 11; HEPES, 11; ATP, 2; pH 7.2 with KOH,
micropipettes were back-filled with the same solution. The Ag/AgCl electrode wire was
threaded into the micropipette and mounted onto a micromanipulator (Sutter). After
gradually lowering the tip to make contact with the cell membrane, gentle suction was
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applied to form a gigaseal and further suction to quickly break the membrane and allow
electrical access to the cell interior.
Once a stable patch was achieved, recordings were taken approximately every minute
following. STO-609 (100 µM, Tocris) was applied after achieving several baseline
recordings. In later experiments, the BKCa channel blocker paxilline (1 µM, Sigma) was
applied prior to, and in conjunction with STO-609. Procedural methods were otherwise
identical.
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Figure 8
Schematic illustrating the lab setup for the electrophysiology experiments.
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STATISTICS
Data are presented as mean ± S.E.M. Differences between individual means were
determined by a paired or unpaired Student’s t-test as appropriate. A value of P < 0.05 was
taken to indicate statistical significance.
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III: RESULTS

CALCIUM IMAGING CONTROL EXPERIMENTS
Initial experiments were to see if intracellular Ca2+ increase during hypoxic exposure
(10 Torr) could be altered by the CamKKβ inhibitor STO-609 (100 μM). Intracellular
calcium concentration is an indicator of cellular excitation. In hypoxia-depolarized Type I
cells, intracellular calcium levels rise to induce neurosecretion. Therefore, calcium imaging
was the technique chosen to examine this topic. It was expected that STO-609 would
attenuate the hypoxic response in mouse Type I cells by inhibiting the CamKKβ/AMPK
cascade thereby prevent a rise in intracellular Ca2+ concentrations (see Figure 9). However,
as STO-609 is not a commonly used or well-researched drug, control experiments were first
performed on resting, normoxic Type I cells to discern whether or not STO-609 had any
unforeseen extraneous or artefactual effects.
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Figure 9
Plot illustrating anticipated calcium imaging results (using Fura-2) from application of STO609 on a hypoxia-depolarized Type I cell. STO-609 reduces intracellular [Ca2+] over the
course of several minutes and the cell recovers upon removal of the drug.
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CALCIUM IMAGING EXPERIMENTS – FURA-2
The green calcium-fluorescent dye Fura-2 was used in these experiments due to its
common laboratory use and ratiometric properties.
Isolated, resting Type I cells loaded with Fura-2 (5 µM) were perfused with normoxic
Tyrode’s solution. Application of STO-609 (100 µM) caused an increase in 340 and 380 nm
fluorescence in both the presence and absence (blank area of coverslip) of cells and
decreased upon drug removal (see Figure 10). Both the 340 and 380 nm signals increased
upon drug application instead of opposing one another. The 380 nm fluorescence increased
faster than 340 nm fluorescence in both instances, resulting in an overall decrease in signal
ratio. The changes in fluorescence were observed within seconds of STO-609 application,
which is uncharacteristically rapid (Hawley, 2005).
The changing background fluorescence indicated that STO-609, which is green in
solution, likely autofluoresces in the green spectrum (510 nm). To avoid this signal artefact, a
calcium dye that fluoresces in the red spectrum was used in subsequent experiments.
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Figure 10
A.i. No cell, raw trace. Fura-2 fluorescence increases with application of STO-609 and
decreases upon removal. A.ii No cell, ratio 340/380. The ratio of the raw traces decreases
with drug application and increases upon removal. B.i. Type I Cell, raw trace. Fura-2
fluorescence increases with application of STO-609 and decreases upon removal. B.ii. Type I
Cell, ratio 340/380. The ratio of the raw traces decreases with drug application and increases
upon removal.
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CALCIUM IMAGING EXPERIMENTS – X-RHOD-1
Isolated, resting Type I cells loaded with the red calcium-fluorescent dye X-Rhod-1(5
µM) were perfused with normoxic Tyrode’s solution. A high K+ challenge was used to
depolarize the cell. Though it did not recover, STO-609 (100 µM) was applied regardless.
The drug caused a rapid decrease in X-Rhod-1 emission fluorescence and reversal upon
removal (Figure 11). Because a high K+ depolarization does not operate via the CamKKβ
pathway, it was not expected that STO-609 would cause a decrease in fluorescence levels.
Background fluorescence (no cell) levels did not change over the course of the experiment,
indicating that the artefactual effect of the drug’s green color had been successfully
eliminated.
At this point, it became clear that the effect seen may be due, at least in part, to
interactions between STO-609 and the dyes independent of the cell. Since hypoxic
depolarization is not required to examine this effect, the remaining calcium imaging
experiments were carried out in mouse neuroblastoma cells (N2A), which are easy to divide
and culture, instead of mouse Type I cells, which must be dissected out, are fragile, and have
low yields.
Experiments were repeated in resting N2A cells. Application of STO-609 (100 µM)
caused a rapid decrease in emission fluorescence and reversal upon drug removal. Resting
cells characteristically have low intracellular Ca2+ levels, thus such a dramatic decrease in
fluorescence seen here was not expected. Once again, background fluorescence (no cell)
levels showed no change.
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To discern if any portion of these effects are also artefactual and not caused by STO609 acting via the CamKKβ pathway, the following experiment was designed to eliminate
Ca2+ itself as a variable.
If a decrease in fluorescence levels is seen in the presence of 0 mM Ca2+, then the
effect must be artefactual, as there is no Ca2+ to bind and unbind to the dyes and alter their
fluorescence emission.

44

Figure 11
A.i., B.i. No Cell. High K+ perfusion (A.ii.) and application of the drug (A.ii., B.ii.) result in
no fluorescence change. A.ii. Type I cell. The cell is depolarized with a high K+ perfusion,
but fails to recover. Application of STO-609 caused a decrease in X-Rhod-1 fluorescence and
an increase upon removal. B.ii. N2A Cell. X-Rhod-1 fluorescence decreased with STO-609
application and increased upon removal.
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CALCIUM IMAGING EXPERIMENTS – IONOMYCIN
Changes in calcium-fluorescent dye emissions correlate directly with changes in
intracellular [Ca2+]. If Ca2+ is eliminated as an experimental variable, then any fluorescence
changes seen after application of STO-609 must be artefactual – possibly due to direct drugdye interaction. To do this, a calcium ionophore Ionomycin (2 µM) was used to perforate the
cell membrane, allowing free passage of Ca2+. This, in conjunction with a 0 mM Ca2+
HEPES solution with added EGTA (5 mM) was perfused over N2A cells loaded with Fura-2
and repeated in N2A cells loaded with X-Rhod-1. After a 0 Ca2+ baseline was reached, STO609 (100 µM) was applied. Fluorescence emission signals immediately decreased upon drug
application and subsequently recovered upon drug removal for both experiments (see Figure
12). The Fura-2 data were background subtracted to account for the STO-609
autofluorescence in the 510 nm range.
These changes in fluorescence levels without any Ca2+ present suggest that STO-609
may be directly interacting with the dyes and causing artefacts. Continuing to test different
calcium fluorescent dyes may well result in a repeat of the pattern of artefacts, thus a
different experimental approach was ultimately recommended.
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Figure 12
A. N2A Cell. Background subtracted data of N2A cells loaded with Fura-2. Application of
STO-609 decreased emission signal in the presence of 0mM Ca2+, indicating artefact. B.
N2A Cell. Background subtracted data of N2A cells loaded with X-Rhod-1. Application of
STO-609 decreased emission signal in the presence of 0mM Ca2+, indicating artefact. 0mM
Ca2+ solution containing 5mM EGTA and 2 μM ionomycin was applied to cells loaded with
each dye causing the large, initial spike as the bath calcium temporarily mixed with the
intracellular solution before washing out of the cell.
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ELECTROPHYSIOLOGY CONTROL EXPERIMENTS
Instead of indirectly measuring cellular activity via intracellular calcium levels,
cellular activity can be directly measured via electrophysiology. As was done with the
calcium imaging experiments, control electrophysiology experiments were first performed on
resting, normoxic Type I cells prior to excited, hypoxia-depolarized Type I cells to account
for any unforeseen interactions and/or effects.
Type I cells exhibit small outward potassium currents at rest. These potassium
channels close as the cell is exposed to hypoxia, leading to depolarization of the cell
membrane, opening of voltage-gated calcium channels, an influx of intracellular calcium, and
neurosecretion (see Figure 3). Furthermore, upon depolarization large conductance voltageactivated K+ currents are activated to repolarize the cell. However, in the presence of hypoxia
a component of these (the BKCa currents) are inhibited. As such, hypoxia-exposed cells
should display substantially reduced outward K+ currents. Therefore, if CamKKβ is involved
in the upstream control of the AMPK cascade that aids in the closing of these K+ channels,
then application of the CamKKβ inhibitor STO-609 during hypoxic exposure may result in
an attenuated effect of hypoxia – currents somewhere between the resting and hypoxic levels
(see Figure 13). Applied to an unstimulated cell, STO-609 is not expected to have any effect
(unless AMPK has tonic activity), but it may inhibit any stimulated closing of these K+
channels by way of AMPK, and thus increase outward-moving currents.
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Figure 13
Current-voltage (I-V) plot illustrating expected electrophysiology results from application of
STO-609 on a hypoxia-depolarized Type I cell. Example corresponding raw current traces at
+20 mV shown inset. Normoxic outward currents are substantially reduced upon hypoxia
exposure. Applying STO-609 during this exposure might be expected to attenuate the
hypoxic inhibition.
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ELECTROPHYSIOLOGY EXPERIMENTS – STO-609
Traditional whole-cell configuration of the voltage-clamp technique was used. A
programmed voltage step protocol from -80 mV to +60 mV in 10 mV steps at 200 ms
duration per step was used. Protocols were executed at one minute intervals. Once a
gigasealed patch was achieved and several stable baseline recordings were taken, STO-609
was applied to the cells for several minutes. If the cell did not detach during this period,
STO-609 was removed to observe any reversal effects.
Application of STO-609 (100 µM) caused a rapid decrease in evoked outward current
(see Figure 14). Measured at +10 mV, currents were reduced by an average of 51.78 pA
±19.73, (n=5). This decrease was statistically significant (P = 0.029). The recordings did not
last long enough to observe any effects of drug removal. This effect is the reverse of what
might be expected of STO-609. Notably, the raw traces observed after STO-609 application
appeared smoother and more level. This could indicate that STO-609 may be inhibiting
large-conductance Ca2+-activated potassium channels (BKCa), the opening and closing of
which is visible on raw traces, making them appear rugged. If STO-609 is selectively
inhibiting these channels, then applying a BKCa blocker prior to and in conjunction with
STO-609 should prevent any further channel inhibition and current reduction by the drug.
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Figure 14
Example I-V plot from an isolated Type I cell. Application of STO-609 caused a decrease in
outward current. Corresponding raw current traces at +20 mV shown inset.
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ELECTROPHYSIOLOGY EXPERIMENTS – STO-609 + PAXILLINE
Paxilline is blocker of large-conductance calcium-activated potassium channels
(BKCa). Application of this inhibitor will reduce outward currents by blocking these
channels. If STO-609 is responsible for any inhibition of BKCa channels, then application of
it after and in conjunction with paxilline should result in no further reduction in current.
Application of paxilline (1 µM) caused a decrease in outward current relative to
baseline recordings over the course of several minutes (see Figure 14). Measured at +20 mV,
currents were reduced by an average of 75.10 pA ±18.22 (n=3). This decrease was
statistically significant (P = 0.027). Once no further reduction was observed, STO-609 (100
μM) was applied in conjunction with the paxilline (1 µM). Currents either decreased slightly
or not at all (see Figure 15). Measured at +20 mV, currents were reduced by an average of
35.77 pA ±17.94, (n=3), but this mean reduction was not statistically significant (P = 0.092).
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Figure 15
Example I-V plot from an isolated Type I cell. Application of the BKCa channel inhibitor
Paxilline caused a decrease in current. Application of Paxilline and STO-609 caused no
further decrease in current. Corresponding raw traces at +20 mV shown inset.
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IV: DISCUSSION

The results of this thesis illustrate two major findings: STO-609 directly interacts and
alters the fluorescent properties of the Ca2+-fluorescent dyes Fura-2 and X-Rhod-1, and that
STO-609 selectively inhibits BKCa channels. This is the first time that either of these
artefactual effects has been observed. Each will be discussed in kind.
The calcium imaging data shows that the application of STO-609 caused artefactual
changes in the fluorescent emissions of both Fura-2 and X-Rhod-1. The rapid pace at which
the drug showed effects, the decrease in intracellular calcium in a non-hypoxically excited
cell, and the large effect seen on resting intracellular calcium levels were all signs that
indicated the data may be artefactual. The ionomycin experiments, which eliminated Ca2+ as
a variable, confirmed that the drug must be directly interacting with the dyes in both cases.
While it is possible that STO-609 may be compatible with other non-green spectrum
emission dyes, it is likely that it could interact directly with those other dyes in a similar
fashion due to the common mechanism by which they all bind calcium.
The electrophysiology results show that STO-609 selectively interacts with and
inhibits BKCa channels. Not only was it predicted that STO-609 would have the opposite
effect on K+ currents when applied during normoxic conditions (an increase, if anything –
see Fig 13), but the lack of any further significant decrease in currents after the application of
paxilline, a specific BKCa blocker, indicated that STO-609 was without effect on other
channels contributing to the macroscopic current.
This pattern of direct interaction and inhibition suggests that STO-609 may be acting
via the Ca2+-binding domains on these kinases, dyes, and channels. The drug may be binding
competitively at the active site or binding near the active site and altering the shape and
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functionality of the molecules, as it does with CamKKβ (Kukimoto-Niino et al, 2011). It is
therefore recommended that STO-609 not be used in conjunction with calcium imaging
techniques, and caution should be taken when using STO-609 in the presence of other
molecules that bind Ca2+, as it may interfere with their function, although this remains to be
tested. If it is used in the presence of Ca2+-binding elements, then good control experiments
must be performed to ensure that any effects seen from the application of STO-609 is not
artefactual or are via targets other than CamKKβ. Otherwise, alternate techniques or the use
of an alternate specific inhibitor of CamKKβ is recommended.

FUTURE EXPERIMENTS

To bolster the findings that STO-609 inhibits BKCa channels, similar
electrophysiology experiments could be performed on cells that have known BKCa channel
expression but not CamKKβ expression. If application of the drug causes a decrease in K+
currents, then this must be due to direct channel inhibition and not due to indirect influence
from the CamKKβ/AMPK cascade.
Instead of pharmacological inhibition, other experiments using siRNA or shRNA to
specifically knock down CamKKβ could be performed. However, in addition to the potential
off-target effects, transfection and incubation of siRNA and shRNA typically takes 24+
hours, while our experiments using Type I cells must be performed the same day they are
extracted.
It is worth noting that while more experiments could be designed to parse out exactly
with what channel or by which mechanism STO-609 is creating artefactual effects, the end
result of these experiments will not change the ultimate conclusion. STO-609 cannot be used
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to test the original question posed in this thesis – whether or not inhibition of upstream
kinases that activate AMPK can attenuate the hypoxic response in Type I cells. To continue
investigating this topic, a new specific inhibitor of CamKKβ must be used, or the focus must
be shifted to one of the other upstream kinases, LKB1 or TAK1. There is evidence that
another pharmacological inhibitor of CamKKβ exists, KN-93 (Jensen, 2007), however it is
also a potassium channel blocker and therefore would be incompatible with these studies
(Rezazadeh, 2005).

CONCLUSION
STO-609 directly interacts with Fura-2 and X-Rhod-1, altering their fluorescent
properties even in the absence of Ca2+. STO-609 also inhibits outward currents of mouse
Type I cells, likely via large-conductance calcium-activated K+ channels (BKCa). Due to
these novel findings, this drug should not be used in conjunction with calcium imaging
techniques and caution should be taken when using it in the presence of other compounds
that bind Ca2+.
At present, STO-609 is used as a selective CamKKβ inhibitor in a variety of
preparations in many different cell types due to its ease of use as drug. However, these new
data indicate that in addition to care moving forward regarding STO-609’s unanticipated
effects, previous work in which the drug was used in the presence of calcium imaging dyes
or BKCa channels should be carefully scrutinized and potentially reevaluated. For example,
Monteiro, et al showed that “using spectrofluorometry and the Ca2+-sensitive probe Fura-2AM, STO-609 was demonstrated to elicit a rapid increase of [Ca2+]i in MCF-7 cells” (2008).
However, control experiments were not performed to demonstrate the effects of STO-609
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alone on these cells, and given the strong evidence presented here that STO-609
autofluoresces in the green spectrum, it is possible that their results and the conclusions they
drew from them may be erroneous.
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